MLLNF.US Malin Corporation plc

Healthcare Drug Manufacturers - Specialty & Generic USA Stocks
7.52 USD
Close of Nov 15, 2026
6.40 7.52
Market cap
USD 32.5M
P/E
-
P/B
0.15x
ROE
0.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2024.

Is MLLNF.US undervalued?

Graham number

The Graham number of Malin Corporation plc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Malin Corporation plc fundamental analysis

No fundamental analysis for Malin Corporation plc yet.

Malin Corporation plc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Malin Corporation plc

Malin Corporation plc, together with its subsidiaries, operates as an investment company in Europe and North America. It engages in the investment in life sciences and healthcare companies targeting various therapeutic areas, including oncology, immunology, and genetic diseases. The company was incorporated in 2014 and is headquartered in Dublin, Ireland.

Full company profile